Impulse - Meeting Healthcare Pioneers

Disclaimer: Blythe and I both work for Roche; nevertheless, all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. What's really behind the term "real-world data" in clinical science? And what can it actually be used for? I asked Blythe Adamson of Flatiron Health to find out the answer. It turns out real-world data is all the medical data collected in the “real world”, meaning outside of any clinical trial. In other words, it's the vast majority of medical data that exists. This includes everything from the results of blood tests, scans, and vaccinations to doctors' handwritten notes. While the idea of using it to develop new treatments seems obvious, the reality is far from simple. Because access to this data is disparate and varies from one country to another. Because the diversity of their modality renders their interpretation complex. And because until recently, we did not have the computational tools to make it work. But now, in the age of AI and mass digitalisation of healthcare, all of this is changing at lightning speed. Drawing on her expertise at the intersection of epidemiology, data science, and health policy, Blythe walks us through the immense challenges and opportunities of real-world data, and how they are poised to revolutionise the development of tomorrow's therapies. An episode to understand precision medicine and the central role of real-world evidence! Timeline: 00:00:00 - Blythe’s background at the interface of epidemiology, data science, and health policy 00:09:33 - The power of real-world data in medicine and drug development 00:17:11 - The barriers to accessing and leveraging real-world data at scale 00:20:26 - Two examples where AI can help make sense of real-world data 00:25:46 - Traditionally overlooked real-world data modalities in medicine 00:27:52 - Breaking down language barriers across real-world datasets 00:35:10 - Some predictions on the next AI-driven breakthroughs in oncology What we also talked about with Blythe: Operation Warp Speed Resilience Patient-Reported Outcome Measures (PROMs) Trusted Research Environments De-identification American Society of Clinical Oncology (ASCO) Circulating tumor DNA (ctDNA) American Heart Association European Society of Cardiology We cited with Blythe some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin As Blythe mentioned during the episode, you can visit her blog at blytheadamson.com for more information about her work. The book recommended by Blythe is Spillover: Animal Infections and the Next Human Pandemic by David Quammen. You can get in touch with Blythe via LinkedIn, and follow the activities of Flatiron Health on LinkedIn, X, and Instagram. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#48 - Driving precision medicine with real-world data - Blythe Adamson - Flatiron Health" on your preferred streaming platform.

How can we solve the puzzle of regulating AI in healthcare? This is the question that Dr. Ricardo Baptista Leite and his team at HealthAI - The Global Agency for Responsible AI in Health ask themselves every day. Their goal? To help international organizations, governments, and local stakeholders strike a balance between regulation and access to the latest innovation in the field. A thorny equation, considering the speed of progress in AI and the time it takes to establish a regulatory framework that, by definition, applies in the long term. With passion and enthusiasm, Ricardo shares the approach they are taking to achieve their mission: by fostering a global community to share best practices and adverse events, by building tailored in-country mechanisms aligned with international guidelines, and by curating the most comprehensive directory of registered AI solutions, which countries and innovators can consider. One thing seems certain: we must evaluate these new technologies from a risk-benefit perspective, drawing on the well-known methods of post-market monitoring that have been applied to pharmaceutical products for decades. A way to remain critical of their use, grant patients and healthcare professionals access to them, and to drive this transformative shift with confidence and security. Timeline: 00:00:00 - Ricardo’s background at the interface of medicine, research, and health policy 00:04:55 - Why we are at a turning point in healthcare 00:08:33 - HealthAI’s role in translating international guidelines for AI use in healthcare to local realities 00:13:08 - Bridging long-term regulation and rapid technological progress 00:21:55 - Curating the right AI solutions in healthcare 00:25:55 - Building trust and adoption among clinicians and patients 00:32:26 - The parallel between elevators and AI in healthcare 00:37:30 - The potential of AI for predictive population health management What we also talked about with Ricardo: HIMSS Europe Software as a Medical Device (SaMD) Stéphanie Allassonniere Agentic AI Ambient AI Elisha Otis As Ricardo mentioned during the episode, you can learn more about HealthAI here and follow their activities on LinkedIn, X, Instagram, and YouTube. The books recommended in the episode include AI Snake Oil: What Artificial Intelligence Can Do, What It Can’t, and How to Tell the Difference by Arvind Narayanan and Sayash Kapoor, Outlive: The Science and Art of Longevity by Peter Attia, and Power and Progress: Our Thousand-Year Struggle Over Technology and Prosperity by Daron Acemoglu and Simon Johnson. We both strongly recommend the newsletter Ground Truths by Dr. Eric Topol, a reference for staying up to date on the latest advances in medicine. You can get in touch with Ricardo via LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode, type "#47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI" on your preferred streaming platform.

When we think of the term "medicine," one of the symbols that comes to mind is the stethoscope. Its use in almost every physical examination by healthcare providers makes it one of the most iconic and widely recognized medical devices. Despite the emergence of digital technologies and the first electronic stethoscopes, their operating principle and design still rely heavily on the patent filed by Dr. David Littmann in the 1960s. But in the era of miniaturization and artificial intelligence, there is a reason to believe that the stethoscope is ripe for a true transformation. Among those who share this opinion are Lapsi Health and the team of Diana van Stijn. Inspired by her experience as a pediatrician and the central role of body sounds in her profession, Diana envisions a new kind of stethoscope—without tubing, fitting in the palm of a hand, and leveraging the latest technological advancements to better equip physicians. This vision gave birth to Keikku, a next-generation digital stethoscope. Beyond rethinking the format and use of the stethoscope for doctors, Diana and her colleagues imagine a future where patients can use it themselves, paving the way for continuous auscultation. In this episode, we explore how Diana and her team are turning this vision into reality, and what it could mean for the prevention, detection, and monitoring of diseases, extending far beyond pediatrics. With humor and enthusiasm, Diana also shares a few secrets about her approach to balancing clinical practice, motherhood, and entrepreneurship in healthcare! Timeline: 00:00:00 - Diana’s background as a Pediatrician, startup Co-Founder, and former National Team Swimmer 00:11:10 - The role of body sounds in medicine 00:15:08 - Early ideas on disrupting traditional stethoscopes 00:22:21 - Building Keikku, a portable, intuitive, and radically modern stethoscope 00:26:43 - Incorporating AI in the interpretation of body sounds 00:30:50 - Moving toward continuous auscultation and getting Keikku into the hands of patients What we also talked about with Diana: Shavini Fernando MedTech World Cirque du Soleil Jhonatan Bringas Dimitriades Magnetic Resonance Imaging Computed Tomography As Diana mentioned during the episode, you can learn more about Keikku here and the other devices in Lapsi Health’s pipeline via their official website. To dive further into some of the topics mentioned in the episode, Diana recommends reading Intelligence-Based Medicine: Artificial Intelligence and Human Cognition in Clinical Medicine and Healthcare by Anthony C. Chang and the article published on JMIR Publications that she co-authored, Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in Pediatrics by Bhargava H. et al. You can follow Lapsi Health’s activities on LinkedIn, and get in touch with Diana via LinkedIn too! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#46 - Rethinking the stethoscope and its use - Diana van Stijn - Lapsi Health" on your preferred streaming platform.

Do you have to come close to death to invent a groundbreaking medical device? That’s certainly not something we would wish upon every medtech entrepreneur. But it is the story of Shavini Fernando and the connected earring OxiWear that she developed. Shavini lives with Eisenmenger syndrome, a condition where the two ventricles of her heart communicate. This condition dramatically increases the pressure in her pulmonary vasculature and severely limits the oxygen carried in her blood. It’s a critical situation that has already caused her four cardiac arrests and three strokes, all of which she has survived. Constantly reliant on supplemental oxygen to live, she dreamed of a way to measure her oxygen levels in real time while staying active. This would allow her to anticipate sudden variations in the future and the life-threatening risks they bring. And she made that dream come true by creating the first connected earring, FDA-certified, capable of measuring blood oxygen saturation in real time. All in a discreet format, lighter than an AirPod, and designed for use during everyday activities, including sports. In many ways, this innovation has transformed her own life, as well as those of hundreds of patients who have benefited from it so far. In this episode, we revisit her story as a patient and survivor. Shavini opens up about the immense challenges of living with Eisenmenger syndrome and developing OxiWear, sharing her vision for this technology and the potential it holds for the future of cardiorespiratory monitoring. A touching and sincere conversation with a truly exceptional figure in the healthtech ecosystem! Timeline: 00:00:00 - Shavini’s story as a pulmonary hypertension patient surviving four cardiac arrests and three strokes 00:19:13 - Building the first smart earring to continuously measure oxygen levels while staying active 00:25:20 - The design behind OxiWear and the challenges to bring it to life 00:31:24 - The blessing of COVID to access funding and educate the general public about cardiorespiratory health 00:36:57 - Making OxiWear the ultimate cardiorespiratory device for remote patient monitoring 00:39:47 - The business model behind OxiWear from a medical and consumer perspective 00:43:10 - Overcoming the torture of creating a medical device from scratch What we also talked about with Shavini: MedTech World Georgetown University Johns Hopkins University Leonsis Family Entrepreneurship Prize “Bark Tank” created by Ted Leonsis MassMEDIC Renal cholesteatoma Sickle cell anemia Photoplethysmography As we mentioned during the episode, you can watch here the recording of the panel I hosted alongside Shavini at MedTech World in 2024. As Shavini shared in the episode, you can learn more about OxiWear at Oxiwear.com and [Oxiwear.fitness](http://Oxiwear.fitnesshttps://www.oxiwear.fitness/). Although we did not explicitly talk about it, I also recommend you watch Shavini’s TEDx Talk recorded in 2019. You can follow OxiWear’s activities on LinkedIn, Facebook, X, TikTok, and get in touch with Shavini via LinkedIn too! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#45 - Measuring oxygen with a smart earring - Shavini Fernando - OxiWear" on your preferred streaming platform.

One of the greatest fantasies in medicine is to one day be able to offer any patient a therapy perfectly adapted to their profile and needs. A "personalized" medicine. The term was introduced to the public in 1999 through an article in The Wall Street Journal titled "New Era of Personalized Medicine: Targeting Drugs for Each Unique Genetic Profile." The enthusiasm for these next-generation therapies was fueled by advances in DNA sequencing, which hinted at future discoveries in genomics and rapid progress in medicine. Twenty-five years later, it is clear that personalized medicine has become a reality (e.g., for the treatment of cancer or rare diseases), and technological progress continues to bring us closer to this ideal. But while developing new personalized therapies is one approach, identifying the most effective current therapies for each patient is another, equally powerful one. And thanks to the multimodal analysis capabilities enabled by AI, this field is rapidly expanding. Andre Esteva is one of the pioneers in this area, having significantly advanced medical research in this direction before venturing into entrepreneurship to make this technology available broadly. In less than three years, his company Artera has already achieved many things that most healthtech startups take much longer to reach: The launch of the first AI-based predictive test to evaluate treatment response to hormonal therapy in prostate cancer. The inclusion of the test in the National Comprehensive Cancer Network (NCCN) guidelines nationwide. The obtention of federal reimbursement for the test. In this episode, Andre shares his vision of predictive medicine in the AI era, the potential of this technology for complex diseases such as cancer, and the keys to their success and recognition on the international medical scene! Timeline: 00:00:00 - Andre’s background as a researcher and entrepreneur in medical AI 00:06:01 - The origins of Artera and the vision of personalizing therapy for cancer patients 00:09:29 - Why AI is so relevant for predictive and prognostic medical applications 00:11:51 - How the ArteraAI Prostate Cancer test works 00:19:57 - Getting the test included in national guidelines within a year 00:24:16 - Developing further therapy prediction tests for cancer and beyond 00:26:03 - Lessons learned from securing national reimbursement within two years 00:29:22 - Andre’s view on current and future applications of AI in medicine What we also talked about with Andre: Salesforce H&E stain Prostate-specific antigen Chemotherapy Computer vision Large Language Models (LLMs) AI agents AlphaFold NeurIPS Computer Vision and Pattern Recognition Conference Marc Benioff We cited with Andre some of the past episodes of the series: #43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos #41 - Making sense of the gut microbiome - Leo Grady - Jona #40 - Cracking biology through AI - Jean-Philippe Vert - Owkin #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo As Andre mentioned during the episode, you can read their landmark paper published in npj Digital Medicine in 2021 to dive deeper into the technology they have developed. For further information about Artera’s publications and all the scientific work they do, take a look at the News & Insights section of their website. You can follow Artera’s activities on LinkedIn and X, and get in touch with Andre via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#44 - Predicting cancer treatment response - Andre Esteva - Artera" on your preferred streaming platform.

According to the WHO, unsafe medication practices and medication errors are a leading cause of avoidable harm in health systems across the globe. In the European Union alone, this translates to nearly 200,000 deaths annually. The magnitude of this problem has led to global initiatives such as "Medication Without Harm," launched in 2017, aiming to reduce medical errors by 50% over five years. Although there is a need for more data on the results of this initiative, we are far from having reached the goal. The key lies in our ability to access medical information, specifically related to prescriptions. Direct access to reliable information, accounting for individual patient characteristics, and able to fit with the tools used by healthcare professionals. A next-generation medical database, incorporating all known information about medications in structured and interoperable bricks capable of supporting caregivers in safer and more effective prescribing practices. It turns out this database exists and has been developed by Pharmacist Emmanuel Bilbault and his team at Posos! Approved less than a year ago by French health authorities, it offers a new perspective on how to approach medical prescriptions in the era of AI and digital health. A way to give back time to every healthcare professional and ensure an unprecedented level of care quality for patients. We talked with Emmanuel about the creation of this new tool - used today by more than 85,000 healthcare professionals in Europe - and what it changes in our fight against medical errors. Timeline: 00:00:00 - What pushed Emmanuel to quit the Pharma industry and found Posos 00:11:11 - The first multilingual, structured, and encoded drug database to streamline medical prescribing 00:16:31 - How Posos is leveraging AI to supercharge its platform 00:22:54 - Keeping the drug database up to date across geographies 00:24:37 - The impact Posos has on healthcare professionals, patients, and health systems 00:29:59 - Toward providing patient access to Posos’ drug database 00:32:40 - Lessons learned from scaling Posos in France and abroad 00:40:47 - Emmanuel’s view on the current healthcare transformation What we also talked about with Emmanuel: Teva Pharmaceuticals IBM’s Watson Health Electronic Health Records SNOMED CT ICD-10-CM ATC MedDRA Named Entity Recognition Optical Character Recognition Word Embedding Machine Learning Pharmagest Ambient AI Nabla We cited with Emmanuel some of the past episodes of the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens As mentioned by Emmanuel during the episode, we recommend taking a look at this page to learn more about the SNOMED CT clinical terminology, as the most comprehensive, multilingual clinical healthcare terminology in the world. You can follow Posos’ activities on LinkedIn, Instagram, and X, and get in touch with Emmanuel via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos" on your preferred streaming platform.

What will the future of surgery look like? According to Dr. George Papagiannakis, we must count on virtual simulation. After all, simulators are an integral part of professional training in highly demanding fields like aviation or F1. So why not medicine? The approach might seem futuristic, but George and his team at ORamaVR share a vision that makes a lot of sense. Integrating extended reality in surgery means increasing the volume of hours spent operating. It means preparing each surgery on a virtual patient with properties close to the real case. It means simulating complications and unforeseen situations safely. And it means reducing the risk of errors in the real world. Following his motto "never first time with the real patient", George immerses us in the universe of extended reality and reveals its potential for medicine and surgery. What is extended reality? What makes a good virtual medical simulation? And what is the impact of this technology today and in the future? Many questions that George addresses with passion and enthusiasm, in a conversation reminiscent of Ready Player One! Timeline: 00:00:00 - Addressing the millions of fatal medical errors worldwide 00:05:20 - Defining extended reality and underlying technologies 00:07:31 - Medical applications of extended reality 00:10:52 - The impact of extended reality on medical training and practice 00:16:25 - What makes a virtual medical environment feel real 00:23:32 - How to recreate the feel of touch and dexterity virtually 00:29:28 - Enabling all healthcare professionals to create virtual environments with AI What we also talked about with George: Prof. Shafi Ahmed Apple Vision Pro Magic Leap Microsoft HoloLens NHS The Anatomy Lesson of Dr. Nicolaes Tulp by Rembrandt IKEA Global illumination Dall-E ChatGPT NotebookLM Frost & Sullivan Meta We cited with George some of the past episodes of the series: #9 - Creating the Gran Turismo of surgery - Raimundo Sierra - Virtamed #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health #32 - Accelerating radiology with AI - Amine Korchi - Radiologist #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy As mentioned by George during the episode, we recommend taking a look at some of the simulations available on the official YouTube channel of ORamaVR, it will bring to life many aspects that we discuss in the episode! You can follow ORamaVR’s activities on LinkedIn, Instagram, and get in touch with George via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#42 - Extending reality to transform surgery - George Papagiannakis - ORamaVR" on your preferred streaming platform.

Our gut contains a world of microorganisms that impact many aspects of our health, well beyond the gastrointestinal system. In fact, more than 30 trillion bacteria, archaea, fungi, and viruses live in the digestive tract of every human, a number that is higher than the number of human cells that make up our body! Each microbiome is unique to an individual, and its genetic heritage represents approximately 100 times that of the human genome. This field is fascinating and science is advancing rapidly, as evidenced by the 2,000 publications generated monthly on the subject. A better understanding of this remarkable ecosystem might bring critical answers to address numerous pathologies and health disorders. This is the mission of Leo Grady and his team at Jona, whose technology enables microbiome analysis based on an at-home test, combined with artificial intelligence to reveal what the current literature says about each person's microbiome. Unveiling the propensity for certain disease risks, along with individual nutritional preferences, Jona can model the body's reaction according to potential changes in the microbiome, and provide valuable insights on behaviors and nutrition that can ultimately improve one’s health. A dive into the heart of the microbiome and its secrets, which today's technology is about to unlock! Timeline: 00:00:00 - Leo’s journey from his PhD in computer vision to AI applications in medicine 00:06:47 - The idea behind Jona and understanding the microbiome better 00:10:33 - What we do know and ignore about the microbiome 00:13:05 - The Jona test kit and what it can interpret from one’s microbiome picture 00:20:17 - The volume and complexity of studies around the microbiome 00:22:11 - The impact of Jona and Leo’s son's story 00:25:38 - Who is Jona for 00:29:00 - Leo’s vision for the future of Jona and AI in healthcare What we also talked about with Leo: Neural networks Siemens HeartFlow Paige AI Memorial Sloan Kettering Crohn’s disease Thomas Clozel We cited with Leo some of the past episodes of the series: #32 - Accelerating radiology with AI - Amine Korchi - Radiologist #35 - Making surgery smarter and safer - Björn Von Siemens - Caresyntax #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo #40 - Cracking biology through AI - Jean-Philippe Vert - Owkin As mentioned by Leo during the episode, we recommend looking at the Jona Journal which sheds light on the latest findings on the microbiome fueled by their research platform, and understanding the current literature. Leo also recommends listening to The Mind-Gut Conversation Podcast by Emeran Meyer to find out more, and We Contain Multitudes by Sarah Henstra as a complementary read. You can follow Jona’s activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Leo via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#41 - Making sense of the gut microbiome - Leo Grady - Jona" on your preferred streaming platform.

All experts agree: if there's one sector that AI will transform, it's healthcare. Whether it's understanding pathologies, developing personalized treatments, the doctor-patient relationship, diagnostic methods, or creating tools to facilitate the work of healthcare professionals, everything is affected by the ongoing transformation! This revolution raises many expectations and questions about the real impact these new technologies will have on tomorrow's medicine. One of the leading figures in this movement on the international scene is none other than the French-American company Owkin, which aims to be "the first end-to-end AI biotech company," whose R&D activities are overseen by Jean-Philippe Vert, himself a true pioneer in the field of machine learning and computational biology. The first “AI-first” biotech company of its kind, bringing a breath of fresh air to an industry known for being extremely costly and time-consuming. So how does AI accelerate the development of new therapies? What is its role in identifying new molecules and targets? How can it be used to create new diagnostic tools? Can we leverage patient data without compromising their safety and privacy? And what can we expect from future models and their impact on our understanding of biology? These are all fascinating questions that Jean-Philippe breaks down with pedagogy and realism, shedding light on one of the most exciting fields of medicine in this era! Timeline: 00:00:00 - Jean-Philippe’s background at the interface of mathematics, computer science, and life sciences 00:07:10 - Owkin’s mission to become the first end-to-end AI biotech firm 00:09:48 - Leveraging AI for drug discovery and new treatment modalities 00:14:35 - Selecting target indications and therapeutic areas 00:17:13 - Changing the way we run clinical trials through AI 00:22:03 - Unlocking patient data across hospitals while preserving safety and privacy 00:25:40 - Developing AI-based diagnostics and driving clinical adoption 00:34:50 - Towards the first AI foundation model to understand biology What we also talked about with Jean-Philippe Google DeepMind Large Language Models (LLMs) Digital twins External control arms Federated learning Digital pathology MSIntuit CRC Bioptimus Neural networks As mentioned by Jean-Philippe during the episode, we recommend taking a look at Owkin and Bioptimus websites as well as their respective Publications & News section to learn more about their technology and stay posted on their latest activities. If you are a data scientist or machine learning enthusiast, you can tackle one of the many biology-related challenges proposed by Kaggle on their platform. To learn more about Owkin’s portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Pipeline section. You can follow Owkin’s activities on LinkedIn, X, and YouTube, and Bioptimus on LinkedIn and X. To get in touch with Jean-Philippe, contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#40 - Cracking biology through AI - Jean-Philippe Vert - Owkin" on your preferred streaming platform.

Among pioneering companies in connected health devices, few have been as forward-thinking as Withings, a flagship of French technology. Their first connected scales date back to 2009 (when smartphones were still emerging!) and remain the industry standard today. For that time, it was a subtle blend combining sleek design, intuitive user experience, and medical precision. A formula that Withings has successfully applied and developed in many other areas, from smartwatches to sleep sensors, thermometers, blood pressure monitors, or even a urinalysis device for your toilet! Their portfolio covers a wide range of medical parameters and helps hundreds of thousands of individuals manage their health daily. Matthieu Menanteau is one of the minds behind Withings' creations over the past 8 years. In this highly insightful episode, he shares Withings' philosophy and approach to creating the ultimate connected health experience, one that allows everyone to better understand themselves and take control of their health journey. We discuss: Withings' philosophy to innovate successfully in today's connected health sector Three development pillars that form the essence of Withings products The ongoing integration of consumer health with health systems and telemedicine The power of continuous medical data in the age of AI and big data A conversation that brings new perspectives on the future of connected health, and how technology can integrate into our daily lives to guide us toward healthier behaviors! Timeline: 00:00:00 - Withings’ origins and vision for connected health 00:07:18 - Providing the ultimate health companion 00:10:03 - Biomarkers and indications covered by Withings 00:13:11 - A home urinalysis laboratory 00:17:44 - Bringing the medical check-up at home 00:21:11 - A dual approach to driving innovation in connected health 00:26:20 - Towards an overwhelming mass of connected health devices? 00:31:47 - Withings’ three pillars of product development 00:38:05 - The role of AI in creating the ultimate connected health experience What we also talked about with Matthieu: Type 2 diabetes Lean mass Visceral fat Hydration pH Vitamin C Ketones Oxygen saturation Cuffless blood pressure measurement Apple CE mark FDA Edge computing Doctolib Alan CES We cited with Matthieu some of the past episodes of the series: #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden As mentioned by Matthieu during the episode, we recommend taking a look at the Research section of the Withings website, to learn more about current and future publications surrounding their products. To learn more about their portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Products section. You can follow Withings’ activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Matthieu via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website!

To discover the whole episode type "#39 - Crafting the best connected health experience - Matthieu Menanteau - Withings" on your preferred streaming platform